Literature DB >> 24443139

Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles.

Kathleen A Ross1, Hyelee Loyd, Wuwei Wu, Lucas Huntimer, Michael J Wannemuehler, Susan Carpenter, Balaji Narasimhan.   

Abstract

Although H5N1 avian influenza has not yet acquired the capacity to readily infect humans, should it do so, this viral pathogen would present an increasing threat to the immunologically naïve human population. Subunit vaccines based on the viral glycoprotein hemagglutinin (HA) can provide protective immunity against influenza. Polyanhydride nanoparticles have been shown to enhance efficacy of subunit vaccines, providing the dual advantages of adjuvanticity and sustained delivery resulting in enhanced protein stability and immunogenicity. In this work, a recombinant trimer of H5 (H53 ) was encapsulated and released from polyanhydride nanoparticles. Release kinetics of the encapsulated H53 were found to be dependent on polymer chemistry (i.e., hydrophobicity and molecular weight). Polyanhydride nanoparticles composed of sebacic anhydride and 1,6-bis(p-carboxyphenoxy)hexane (CPH; that degrade into more acidic monomers) released structurally stable HA H53 , while H53 released from formulations composed of CPH and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) (that are amphiphilic and whose degradation products are less acidic) displayed unfolding of tertiary structure. However, the antigenicity of the H53 based on binding of a H5-specific monoclonal antibody was preserved upon release from all the formulations studied, demonstrating the value of polyanhydride nanoparticles as a viable platform for HA-based influenza vaccines.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  H5N1; hemagglutinin; influenza; nanoparticle; polyanhydride; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24443139     DOI: 10.1002/jbm.a.35086

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  18 in total

1.  Effects of nanoparticles in species of aquaculture interest.

Authors:  Kheyrollah Khosravi-Katuli; Ermelinda Prato; Giusy Lofrano; Marco Guida; Gonçalo Vale; Giovanni Libralato
Journal:  Environ Sci Pollut Res Int       Date:  2017-06-09       Impact factor: 4.223

2.  The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.

Authors:  Emad I Wafa; Sean M Geary; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  Acta Biomater       Date:  2017-01-04       Impact factor: 8.947

3.  pH-Responsive Microencapsulation Systems for the Oral Delivery of Polyanhydride Nanoparticles.

Authors:  Lindsey A Sharpe; Julia E Vela Ramirez; Olivia M Haddadin; Kathleen A Ross; Balaji Narasimhan; Nicholas A Peppas
Journal:  Biomacromolecules       Date:  2018-02-21       Impact factor: 6.988

4.  Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses.

Authors:  Julia E Vela Ramirez; Lorraine T Tygrett; Jihua Hao; Habtom H Habte; Michael W Cho; Neil S Greenspan; Thomas J Waldschmidt; Balaji Narasimhan
Journal:  J Biomed Nanotechnol       Date:  2016-06       Impact factor: 4.099

5.  Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus.

Authors:  Laura M Stephens; Kathleen A Ross; Kody A Waldstein; Kevin L Legge; Jason S McLellan; Balaji Narasimhan; Steven M Varga
Journal:  J Immunol       Date:  2021-04-07       Impact factor: 5.422

6.  Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity.

Authors:  Kathleen A Ross; Hyelee Loyd; Wuwei Wu; Lucas Huntimer; Shaheen Ahmed; Anthony Sambol; Scott Broderick; Zachary Flickinger; Krishna Rajan; Tatiana Bronich; Surya Mallapragada; Michael J Wannemuehler; Susan Carpenter; Balaji Narasimhan
Journal:  Int J Nanomedicine       Date:  2014-12-30

7.  Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity.

Authors:  Danielle A Wagner-Muñiz; Shannon L Haughney; Sean M Kelly; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

8.  Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf.

Authors:  Jodi L McGill; Sean M Kelly; Pankaj Kumar; Savannah Speckhart; Shannon L Haughney; Jamie Henningson; Balaji Narasimhan; Randy E Sacco
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

9.  Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.

Authors:  Luman Liu; Prakash Kshirsagar; John Christiansen; Shailendra K Gautam; Abhijit Aithal; Mansi Gulati; Sushil Kumar; Joyce C Solheim; Surinder K Batra; Maneesh Jain; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Biomed Mater Res A       Date:  2020-08-25       Impact factor: 4.396

Review 10.  Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.

Authors:  Gourapura J Renukaradhya; Balaji Narasimhan; Surya K Mallapragada
Journal:  J Control Release       Date:  2015-09-26       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.